Hey there, time traveller!
This article was published 27/11/2012 (1723 days ago), so information in it may no longer be current.
Kane Biotech Inc., the Winnipeg company that is developing compounds that prevent and remove microbial biofilms, has received regulatory approval this month that should pave the way for it to launch its first two products on the market early in the new year.
Today it got approval from the Therapeutic Products Directorate of Health Canada for KBI Antibacterial Hard Surface Disinfectant for use in a wide range of commercial and industrial settings like hospitals, food processing plants, institutional/industrial and barn facilities.
Last week it received approval from the Low Risk Veterinary Health Products to launch its oral pet care product in Canada.
The granting authority is in cooperation with Health Canada and the Canadian Animal Health Institute.
Kane already has a partner lined up to manufacture and distribute the hard surface disinfectant. Avmor Ltd. of Laval, Que., Canada’s leading manufacturer of professional cleaning solutions aimed at the janitorial, sanitation and foodservice markets, will launch KBI in January.
Kane CEO Gord Froehlich said discussion are well underway to have a manufacturer and distributor in place for its oral pet care product called StrixNB so that it, too, will likely be on the market early in the new year.
In other developments, earlier this year the company renewed its cooperative research and development agreement with the U.S. Army Institute of Surgical Research in Fort Sam Houston, Texas.
Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. They develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract.
Earlier this month it initiated a private placement offering including warrants to try to raise about $1.5 million.
Kane’s shares are unchanged this morning at eight cents.